New treatment options and biomarkers for managing enlarged prostate
Official title: New Treatment Strategies and Epigenetic Biomarker for Management of BPH
Funded at Beth Israel Deaconess Medical Center · NIH-11062157 · Data updated 2026-11-12
This study is looking into why some men over 50 with benign prostatic hyperplasia (BPH) don’t get relief from the usual medication, finasteride, and aims to find new treatment options by exploring how certain changes in genes and inflammation might affect their symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 20, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $598,609 |
| NIH project number | 1R01DK142211-01 |
| Project ID | NIH-11062157 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adult males over 21 years old who experience lower urinary tract symptoms due to BPH.
✕Less likely to help
Patients who do not have benign prostatic hyperplasia or those under 21 years old may not benefit from this research.
What this research studies
This research investigates new treatment strategies for benign prostatic hyperplasia (BPH), a condition affecting many men over 50. It focuses on understanding why some patients do not respond to the common medication finasteride, which is used to alleviate symptoms. The study will explore the role of epigenetic changes in the SRD5A2 gene, which is crucial for prostate health, and how inflammation and other factors may influence its expression. By identifying these mechanisms, the research aims to develop more effective treatments for BPH.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for men suffering from BPH, enhancing their quality of life.
How similar studies have gone: Previous research has shown promise in understanding the genetic and epigenetic factors influencing BPH, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Olumi, Aria F — Beth Israel Deaconess Medical Center
- Study coordinator: Olumi, Aria F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.